These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 19264554)

  • 21. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
    Koh C; Melling CV; Jennings C; Lewis M; Goyal A
    J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
    Kim SW; Choi JH; Lee YS; Han SW; Im YJ
    Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
    Ghalayini IF; Al-Ghazo MA; Elnasser ZA
    Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
    Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
    Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
    Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X
    J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onabotulinumtoxin A (Botox): A reasonable alternative for refractory neurogenic bladder dysfunction in children and young adults.
    Softness KA; Thaker H; Theva D; Rajender A; Cilento BG; Bauer SB
    Neurourol Urodyn; 2021 Nov; 40(8):1981-1988. PubMed ID: 34486166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G; Liao L
    Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
    Do Ngoc Thanh C; Audry G; Forin V
    J Pediatr Urol; 2009 Dec; 5(6):430-6. PubMed ID: 19577520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S; Clothier J; Wright A; Garriboli M
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
    Kaviani A; Khavari R
    Urol Clin North Am; 2017 Aug; 44(3):463-474. PubMed ID: 28716326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Marque P; Rischmann P; Gamé X
    World J Urol; 2016 May; 34(5):755-61. PubMed ID: 26282099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum Toxin Injection for Medically Refractory Neurogenic Bladder in Children: A Systematic Review.
    Wu SY; Chang SJ; Yang SS; Hsu CK
    Toxins (Basel); 2021 Jun; 13(7):. PubMed ID: 34203333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.
    Karsenty G; Baverstock R; Carlson K; Diaz DC; Cruz F; Dmochowski R; Fulford S; Giannantoni A; Heesakkers J; Kaufmann A; Peyrat L; Thavaseelan J; Dasgupta P
    Int J Clin Pract; 2014 Jun; 68(6):731-42. PubMed ID: 24472109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
    Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
    Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.
    Kalsi V; Apostolidis A; Popat R; Gonzales G; Fowler CJ; Dasgupta P
    Eur Urol; 2006 Mar; 49(3):528-35. PubMed ID: 16426735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.